Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

RSS icon
Richard Kovacs, MD, MACC, chief medical officer, American College of Cardiology (ACC), former ACC president, and professor of clinical medicine, Indiana University School of Medicine, explains the most important late-breaking cardiology pharmacology trials at the ACC 2025 meeting. #ACC25 #ACC2025

Late-breaking cardiovascular drug trials took center stage at ACC.25

Richard Kovacs, MD, detailed some the most important late-breaking cardiology pharmacology trials presented at ACC.25.

Thumbnail

Deaths after TAVR are on the rise: Is the pandemic to blame or should cardiologists be concerned?

COVID-19 may help explain the increased rates of cardiac and noncardiac mortality among TAVR patients, but there are several other factors to consider as well. Researchers explored nearly 11 years of STS/ACC registry data to learn more.

Venus-PowerX TAVR valve developed by Venus MedTech

Cardiologists perform world’s first TAVR procedures with new fully retrievable valve

Researchers detailed their experience performing the very first TAVR procedures with the Venus-PowerX TAVR valve from Venus MedTech. The valve includes a wire-controlled mechanism that makes it possible to recapture after full deployment. 

Thumbnail

A simple way to ensure more heart patients with severe AS receive the care they need

Sending helpful alerts through email and the electronic health record can make a significant impact on patient care, according to new data presented at ACC.25 and published in Circulation.

Shockwave Medical IVL

Shockwave Medical testing new-look IVL technology on challenging coronary lesions

Care teams throughout the U.S. and U.K. are now exploring the safety and effectiveness of using Shockwave Medical's new Javelin IVL catheters to treat challenging, difficult-to-cross coronary lesions. 

Abbott has received approval from the U.S. Food and Drug Administration (FDA) for its TriClip transcatheter edge-to-edge repair (TEER) system designed to treat tricuspid regurgitation (TR).

CMS proposes Medicare coverage for T-TEER

CMS has proposed covering tricuspid TEER for patients who present with symptomatic tricuspid regurgitation despite optimal medical therapy. The agency still has questions about the available data, however, and is seeking public comments as it makes its final decision.

merger acquisition M&A business

Boston Scientific finalizes Bolt Medical acquisition as FDA clears company’s IVL technology

Boston Scientific hopes to officially launch its new IVL system in the first half of 2026.

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, and a clinical professor of medicine at Wake Forest University School of Medicine, offers what he saw as the main takeaway messages in the ACC 2025 late breaking trials.

Key takeaways from ACC.25: Advances in cardiovascular science

Former American College of Cardiology president Hadley Wilson, MD, executive vice chair of Atrium Health Sanger Heart and Vascular Institute, explains his main takeaway messages from the ACC 2025 late-breaking trials.

Displaying 49 - 56 of 1109
Design by Adaptive Theme